The trend in one sentence
Healthcare is moving upstream: from treating disease after it becomes visible toward identifying risk, intervention opportunities and biological change earlier.
What’s driving it
Four capabilities increasingly reinforce one another: AI, genomics, digital therapeutics and remote monitoring.
AI can identify patterns across complex clinical information. Genomics and biomarkers can reveal individual risk and treatment differences. Connected devices can produce longitudinal information outside the clinic. Digital interventions can make parts of prevention continuous rather than episodic.
None of these eliminates traditional medicine. Together they change when useful intervention can begin.
Why it matters
The economic and human implications are substantial.
Earlier intervention can alter outcomes and costs. It changes the role of primary care, diagnostics, insurance, pharmaceuticals, medical devices and the patient. It also raises difficult questions about privacy, false positives, unequal access and what should happen when a system identifies risk before symptoms exist.
Prediction without a useful intervention is not automatically progress.
What leaders should watch
Watch multimodal clinical AI, liquid biopsy, continuous monitoring, at-home diagnostics, genomic risk assessment, digital therapeutics and reimbursement models that reward prevention.
Also watch the governance layer: clinical validation, explainability, data provenance and the distinction between a useful prediction and an actionable one.
From the foresight archive
Jim Carroll published this as Megatrend #10 in July 2025 and revisited it in August 2026. His retrospective emphasized that the trend was broader than AI alone: genomics, digital therapeutics and remote monitoring were moving in parallel.
That convergence is the important point. Predictive healthcare is not one breakthrough. It is an emerging system.
The strategic question
What changes when healthcare can increasingly know about a risk before the patient feels ill?